FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382751451> ?p ?o ?g. }

• W4382751451 endingPage "e006699" @default.
• W4382751451 startingPage "e006699" @default.
• W4382751451 abstract "Background We used a proliferating ligand (APRIL) to construct a ligand-based third generation chimeric antigen receptor (CAR) able to target two myeloma antigens, B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor. Methods The APRIL CAR was evaluated in a Phase 1 clinical trial ( NCT03287804 , AUTO2) in patients with relapsed, refractory multiple myeloma. Eleven patients received 13 doses, the first 15×10 6 CARs, and subsequent patients received 75,225,600 and 900×10 6 CARs in a 3+3 escalation design. Results The APRIL CAR was well tolerated. Five (45.5%) patients developed Grade 1 cytokine release syndrome and there was no neurotoxicity. However, responses were only observed in 45.5% patients (1×very good partial response, 3×partial response, 1×minimal response). Exploring the mechanistic basis for poor responses, we then compared the APRIL CAR to two other BCMA CARs in a series of in vitro assays, observing reduced interleukin-2 secretion and lack of sustained tumor control by APRIL CAR regardless of transduction method or co-stimulatory domain. There was also impaired interferon signaling of APRIL CAR and no evidence of autoactivation. Thus focusing on APRIL itself, we confirmed similar affinity to BCMA and protein stability in comparison to BCMA CAR binders but reduced binding by cell-expressed APRIL to soluble BCMA and reduced avidity to tumor cells. This indicated either suboptimal folding or stability of membrane-bound APRIL attenuating CAR activation. Conclusions The APRIL CAR was well tolerated, but the clinical responses observed in AUTO2 were disappointing. Subsequently, when comparing the APRIL CAR to other BCMA CARs, we observed in vitro functional deficiencies due to reduced target binding by cell-expressed ligand." @default.
• W4382751451 created "2023-07-01" @default.
• W4382751451 creator A5008908090 @default.
• W4382751451 creator A5011340913 @default.
• W4382751451 creator A5022497270 @default.
• W4382751451 creator A5022750427 @default.
• W4382751451 creator A5023274923 @default.
• W4382751451 creator A5025053751 @default.
• W4382751451 creator A5028678545 @default.
• W4382751451 creator A5030543123 @default.
• W4382751451 creator A5031427216 @default.
• W4382751451 creator A5033604311 @default.
• W4382751451 creator A5035153106 @default.
• W4382751451 creator A5037556744 @default.
• W4382751451 creator A5045712447 @default.
• W4382751451 creator A5046994711 @default.
• W4382751451 creator A5054169683 @default.
• W4382751451 creator A5055440363 @default.
• W4382751451 creator A5055997822 @default.
• W4382751451 creator A5057490890 @default.
• W4382751451 creator A5071377472 @default.
• W4382751451 creator A5074398233 @default.
• W4382751451 creator A5076469181 @default.
• W4382751451 creator A5079191784 @default.
• W4382751451 creator A5081769123 @default.
• W4382751451 creator A5082564837 @default.
• W4382751451 creator A5083385949 @default.
• W4382751451 creator A5089455737 @default.
• W4382751451 creator A5089556001 @default.
• W4382751451 creator A5092371631 @default.
• W4382751451 date "2023-06-01" @default.
• W4382751451 modified "2023-10-18" @default.
• W4382751451 title "Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy" @default.
• W4382751451 cites W1935116877 @default.
• W4382751451 cites W2043316586 @default.
• W4382751451 cites W2069282346 @default.
• W4382751451 cites W2078992149 @default.
• W4382751451 cites W2082708772 @default.
• W4382751451 cites W2102572875 @default.
• W4382751451 cites W2104320462 @default.
• W4382751451 cites W2145026575 @default.
• W4382751451 cites W2153147430 @default.
• W4382751451 cites W2159015766 @default.
• W4382751451 cites W2370823328 @default.
• W4382751451 cites W2422962677 @default.
• W4382751451 cites W2471662063 @default.
• W4382751451 cites W2537846497 @default.
• W4382751451 cites W2567424265 @default.
• W4382751451 cites W2735833312 @default.
• W4382751451 cites W2768823259 @default.
• W4382751451 cites W2773804840 @default.
• W4382751451 cites W2775982617 @default.
• W4382751451 cites W2787301955 @default.
• W4382751451 cites W2801641802 @default.
• W4382751451 cites W2807637103 @default.
• W4382751451 cites W2888746916 @default.
• W4382751451 cites W2924578117 @default.
• W4382751451 cites W2938308258 @default.
• W4382751451 cites W2943335541 @default.
• W4382751451 cites W2982386899 @default.
• W4382751451 cites W2990867581 @default.
• W4382751451 cites W3041575100 @default.
• W4382751451 cites W3097902874 @default.
• W4382751451 cites W3127802833 @default.
• W4382751451 cites W3133229959 @default.
• W4382751451 cites W3133661829 @default.
• W4382751451 cites W3176532045 @default.
• W4382751451 cites W3183792933 @default.
• W4382751451 cites W3207961322 @default.
• W4382751451 cites W4200001065 @default.
• W4382751451 cites W4206956920 @default.
• W4382751451 cites W4230683387 @default.
• W4382751451 cites W4281714381 @default.
• W4382751451 doi "https://doi.org/10.1136/jitc-2023-006699" @default.
• W4382751451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37399355" @default.
• W4382751451 hasPublicationYear "2023" @default.
• W4382751451 type Work @default.
• W4382751451 citedByCount "2" @default.
• W4382751451 countsByYear W43827514512023 @default.
• W4382751451 crossrefType "journal-article" @default.
• W4382751451 hasAuthorship W4382751451A5008908090 @default.
• W4382751451 hasAuthorship W4382751451A5011340913 @default.
• W4382751451 hasAuthorship W4382751451A5022497270 @default.
• W4382751451 hasAuthorship W4382751451A5022750427 @default.
• W4382751451 hasAuthorship W4382751451A5023274923 @default.
• W4382751451 hasAuthorship W4382751451A5025053751 @default.
• W4382751451 hasAuthorship W4382751451A5028678545 @default.
• W4382751451 hasAuthorship W4382751451A5030543123 @default.
• W4382751451 hasAuthorship W4382751451A5031427216 @default.
• W4382751451 hasAuthorship W4382751451A5033604311 @default.
• W4382751451 hasAuthorship W4382751451A5035153106 @default.
• W4382751451 hasAuthorship W4382751451A5037556744 @default.
• W4382751451 hasAuthorship W4382751451A5045712447 @default.
• W4382751451 hasAuthorship W4382751451A5046994711 @default.
• W4382751451 hasAuthorship W4382751451A5054169683 @default.
• W4382751451 hasAuthorship W4382751451A5055440363 @default.
• W4382751451 hasAuthorship W4382751451A5055997822 @default.
• W4382751451 hasAuthorship W4382751451A5057490890 @default.

• next